|
Summary of First Quarter 2013 Performance and Business Outlook
2013.05.15
|
|---|
|
Summary of First Quarter 2013 Performance and Business Outlook
- First-quarter sales up 21.6% year-on-year - Continued drilling success, currently producing approximately 1,500 barrels per day - Expansion of product portfolio in bioprocess and research-use markets
Daehan New Pharm achieved first-quarter sales of 13.02 billion KRW, marking a 21.6% increase compared to the same period last year, despite an overall challenging environment in the pharmaceutical industry following the April 2012 national drug price cuts. Considering that the same quarter last year was before the price reduction policy, the company’s effective growth rate is estimated to be around 30%. Since the third quarter of 2011, sales have shown continuous quarterly growth. Operating profit increased 10.3% to 1.18 billion KRW, while ordinary profit surged 146.2% to 608 million KRW.
The company’s key growth engine lies in strategic innovation—focusing on differentiated obesity solutions as a core business, improving distribution by directly managing hospitals and clinics, and strengthening its network through customer asset-oriented strategies. Daehan New Pharm continues to secure talented professionals to execute these strategies with excellence, reinforce organizational capabilities, and accelerate the cultivation of productivity and core competencies. Furthermore, through strategic overseas expansion based on specialization, focus, and globalization, the company is achieving both growth and globally standardized management practices.
In the resource development sector, continuous drilling success has been reported in the Galaz and BNG contract areas since late 2012. Current daily oil production stands at approximately 1,500 barrels, with a year-end target of 2,000 barrels per day. Preparations are also underway for a 4,700-meter drilling project in the BNG area in the second quarter.
In the bio business, Daehan New Pharm has completed partnership agreements to expand its product lineup beyond cell culture media and Protein A to include seven additional products: four Ion Exchange Chromatography Resins and three Hydrophobic Interaction Chromatography Resins used in purification processes. The company is currently conducting market research in preparation for multiple new product launches.
Daehan New Pharm expects its strong performance trend to continue beyond the second quarter. By focusing on successful drilling operations, increased crude oil production, and early success in its bio business through core product development, the company aims to strengthen its growth engines and solidify its position as a leading mid-sized enterprise. |


Home